Although we obtained similar results in survival using the c-Abl inhibitor Imatinib [14], it is notable that in this work vitamin E supplementation was initiated relatively late, at p28, whereas improvement in NPC mice survival with Imatinib was achieved if treatment was initiated earlier, at p7 [14]. The gene discussed is ABL1; the disease is nasopharyngeal carcinoma.